The mechanism of action of baricitinib includes theoretical advantages over tocilizumab, as baricitinib decreases the concentration of several cytokines and inflammatory mediators involved in the pathogenesis of COVID-19 in addition to IL-6 and has an additional potential antiviral activity (13). The gene discussed is IL6; the disease is COVID-19.